Clinical Trial Update: ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

ChariotMS is evaluating cladribine to halt deterioration in people with advanced and progressive multiple sclerosis. The trial is in Phase 2/Phase 3 and is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAVENCLAD (cladribine)

Snippet

Sponsor: Queen Mary University of London | Conditions: Advanced Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING